跳转至内容
Merck
所有图片(1)

文件

Y0002098

索拉非尼

European Pharmacopoeia (EP) Reference Standard

别名:

4- [4-[[[[4-氯-3-（三氟甲基）苯基]氨基]羰基]氨基]苯氧基] -N-甲基-2-吡啶甲酰胺

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C21H16ClF3N4O3
CAS号:
284461-73-0
分子量:
464.82
MDL號碼:
MFCD06411450
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

sorafenib

製造商／商標名

EDQM

應用

pharmaceutical

格式

neat

儲存溫度

2-8°C

InChI

1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

InChI 密鑰

MLDQJTXFUGDVEO-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

本品按现行药典规定交付。该产品的所有支持信息，包括SDS和任何产品信息宣传页均由药典发行机构制定并发布。如需更多信息和支持，请见现行药典的网站。

應用

索拉非尼（EP参考标准品）仅用于欧洲药典中明确规定的实验室测试用途。

包裝

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

其他說明

可能适用相应的销售限制。

象形圖

Health hazardEnvironment
GHS08,GHS09

訊號詞

Danger

危險分類

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

儲存類別代碼

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ye Kuang et al.
Cancer medicine, 12(6), 7222-7233 (2022-11-25)
Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality. The long-term use of sorafenib, a targeted drug for hepatocellular carcinoma, will lead to drug resistance, and patients are prone to cancer metastasis, the molecular mechanism of which is
Yiliang Wang et al.
Journal of nanobiotechnology, 22(1), 473-473 (2024-08-13)
Hepatocellular carcinoma (HCC) is a highly malignant tumor known for its hypoxic environment, which contributes to resistance against the anticancer drug Sorafenib (SF). Addressing SF resistance in HCC requires innovative strategies to improve tumor oxygenation and effectively deliver therapeutics. In
Baoxin Zhao et al.
Virologica Sinica, 38(5), 680-689 (2023-06-19)
Chronic hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma (HCC). The HBV genome is prone to mutate and several variants are closely related to the malignant transformation of liver disease. G1896A mutation (G to
Zhong Wan et al.
Aging, 12(18), 18192-18208 (2020-10-07)
We investigated MAPK14-dependent resistance to sorafenib in hepatocellular carcinoma (HCC). Bioinformatics analysis and dual luciferase reporter assays in HCC cell lines showed that miR-216a-3p directly binds to the 3'UTR of MAPK14 mRNA and downregulates MAPK14 protein expression. Consequently, miR-216a-3p expression
Su-Hong Chen et al.
Experimental and therapeutic medicine, 23(3), 232-232 (2022-03-01)
Sorafenib is currently used to treat hepatocellular carcinoma (HCC). However, the development of chemoresistance to sorafenib is a major limitation for sorafenib-based therapy in patients with HCC. In the present study, the effect of the combination therapy of sorafenib and

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门